Key result
Ramipril (1.25 or 5.0 mg daily) did not significantly reduce urinary albumin excretion rate compared with placebo over 2 years in normotensive patients with type 1 diabetes (P=0.97 at year 2).
Why the study?
Does ramipril reduce urinary albumin excretion rate in normotensive patients with type 1 diabetes and microalbuminuria?
Population
55 normotensive patients with type 1 diabetes and microalbuminuria (14 women)
Comparison
Ramipril 1.25 mg or 5.0 mg daily for 2 years vs Placebo for 2 years after a single-blind placebo…
Design
RCT, double blind
Follow-up
2 years
Authors
Loading...
No benefit on albuminuria in normotensive type 1 diabetes; challenges ACE inhibitor use without blood pressure reduction.
RCT (n=55)
Double-blind
Does ramipril reduce urinary albumin excretion rate in normotensive patients with type 1 diabetes and microalbuminuria?
p-value: p=0.97
Ramipril did not reduce microalbuminuria in normotensive patients with type 1 diabetes, questioning the clinical use of ACE inhibitors in this population without concomitant blood pressure reduction.
Bojestig et al. (2001) conducted an RCT in Normotensive patients with type 1 diabetes and microalbuminuria (n=55). Ramipril vs. Placebo was evaluated on urinary albumin excretion rate (UAER) (p=0.97). Ramipril (1.25 or 5.0 mg daily) did not significantly reduce urinary albumin excretion rate compared with placebo over 2 years in normotensive patients with type 1 diabetes (P=0.97 at year 2).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: